The collaboration will focus on addressing the drug delivery challenges of poorly soluble molecules with limited oral bioavailability by integrating Quotient’s RapidFACTTM clinical manufacture and testing service with
Psion joined forces with Antra ID to offer an integrated solution that deals with shipping, warehousing, distribution, and inventory control. Psion solution features backward compatibility, modularity and field
The company expects to submit European marketing authorization application (MAA) for Heplisav in the third quarter of 2012. Upon approval of the Heplisav BLA, Dynavax also considers submitting
Ferrer formally notified the European Medicines Agency of its decision. The company submitted the MAA for Egrifta to the agency on 31 May 2011, during which it was
As a part of the agreement, TOLMAR will supply up to nine currently approved and marketed products while Global Pharmaceuticals, Impax’s generics division, will commercialize these products following
The submission is based on Phase 3 AFFIRM trial of enzalutamide in post-chemotherapy prostate cancer patients in which seizure was reported in less than 1% of enzalutamide-treated patients.
Under the multi-year relationship with Eli Lilly and Company, PrimeraDx will develop diagnostic products in support of multiple clinical development programs for novel therapeutics. PrimeraDx president and CEO
Caris Target Now has been updated to offer both on- and off-Compendium therapeutic associations for all solid tumours, across a wide range of evidence. The product identifies the
The OneSource Scientific IT Services include scientific Applications Services, computer systems validation, lab computing services and Scientific Data Services. The new solutions assist customers in minimising the gap
NSI-189, a proprietary new chemical entity, stimulates new neuron growth in the hippocampus, a region of the brain believed to be implicated in MDD as well as other
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.